Novo’s Big Game spot can help reinforce the Wegovy pill’s credibility against copycat compounded versions.

The cash-pay discount hub will offer fewer drugs than GoodRx and have limited reach, but drugmakers must still promote it to drive prescription volumes, especially for uninsured drugs.

Midi Health’s growth shows sustained focus on women’s care can fuel digital health trust and scale.

Weight loss hype pushed Lilly well ahead of Novo, yet Novo’s early pill win signals a turn toward more affordable, convenient obesity treatments.

Most Americans are wary of their use in healthcare, but supervised medical use is starting to feel acceptable.

An FTC settlement and newly passed legislation in Congress scraps rebate tactics and formulary bias, chipping away at PBM pricing power.

Weight loss hype pushed Lilly well ahead of Novo, yet Novo’s early pill win signals a turn toward more affordable, convenient obesity treatments.

The UK-based pharma giant lists its stock on NYSE even as it continues overseas manufacturing and innovation spending.

Costs will shape 2026 midterm votes, with both parties targeting insurers and pharma to lower costs. The industry has a chance to defend its role—and show real affordability gains.

But a crowded obesity market demands product differentiation, fewer side effects, and benefits beyond weight loss to reap financial gains.

Pharma and health brands return to the Super Bowl, ditching drug pitches for brand storytelling campaigns.

Studies link higher AFib detection to watch wearers, strengthening wearables’ medical case.

Novo’s oral drug is wildly outperforming weekly sales needed to hit forecasts, signaling strong early demand for GLP-1 pills.

D2C pharma brands must ensure their cash-pay programs and telehealth ties are transparent and compliant with anti-kickback laws.

Better-staffed pharmacies could become Walmart’s edge, even as more consumers move online.

Rising demand clashes with high costs, no insurance coverage, and doctors’ reluctance to validate outside results.

The revenue hit to pharma should be modest, but drug-pricing headwinds will force manufacturers to trade margin for volume and push harder on prices abroad.

Benefits emerge with adherence, increasing pressure on employers to keep coverage.

More than one-third of Gen Z and millennials turn to AI for stigma-free support.

The healthcare giant’s forecasted decline in revenues signals an industry-wide pivot from expansion to cost discipline.